SCOLR Pharma, Inc. (DDD) has 183 open-market insider trades by 31 insiders since 2006. Over the last six months insiders net sold $635K. The most active filer is G. Walter Loewenbaum II, Director.
| Name | Title | Tier | Trades | Value | Last Trade |
|---|---|---|---|---|---|
| G. Walter Loewenbaum II | Dir | — | 43 | $56.3M | 2018-05-29 |
| Abraham N. Reichental | Pres | — | 9 | $40.0M | 2015-06-02 |
| Charles W. Hull | CTOVP | — | 9 | $21.4M | 2026-09-08 |
| Damon Joseph Gregoire | EVPMergers & Acquisitions | — | 8 | $11.8M | 2014-11-19 |
| Kevin McAlea | COOVP | — | 9 | $10.9M | 2019-03-01 |
| Andrew Martin Johnson | CLOVPSecretary | — | 28 | $3.6M | 2024-04-15 |
| Jeffrey A. Graves | CEOPres | — | 9 | $2.8M | 2026-09-17 |
| Kevin S. Moore | Dir | — | 5 | $2.6M | 2026-05-14 |
| Robert M. Grace Jr. | — | — | 1 | $2.0M | 2012-05-02 |
| Jim D. Kever | Dir | — | 3 | $1.7M | 2026-05-14 |
| Insider | Title | Type | Value | Date |
|---|---|---|---|---|
| Jeffrey A. Graves | CEO & President | Sell | $152K | 2026-09-17 |
| Phyllis B. Nordstrom | CFO & CAO +1 | Sell | $107K | 2026-09-17 |
| Jeffrey A. Graves | CEO & President | Sell | $377K | 2026-08-20 |
| Jeffrey A. Graves | CEO & President | Buy | $231K | 2024-12-17 |
| Charles W. Hull | CTO & VP | Sell | $895K | 2024-12-17 |
| Thomas W. Erickson | Director | Buy | $265K |
Companies that share insiders with DDD, and sector peers with recent insider buying. Related by who files, not by how the stocks move.
| 2023-11-28 |
| Thomas W. Erickson | Director | Buy | $229K | 2023-11-21 |
| Reji Puthenveetil | VP | Sell | $147K | 2023-05-31 |
| Malissia Clinton | Director | Sell | $149K | 2023-05-18 |
| Andrew Martin Johnson | CLO & VP +1 | Sell | $146K | 2022-12-09 |
| Jeffrey A. Graves | CEO & President | Buy | $192K | 2022-11-25 |
| Andrew Martin Johnson | CLO & VP +1 | Sell | $136K | 2022-09-09 |
| Charles W. Hull | CTO & VP | Sell | $578K | 2022-06-08 |
| Jim D. Kever | Director | Buy | $107K | 2022-05-26 |
| Malissia Clinton | Director | Sell | $123K | 2022-05-25 |